These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 10996870

  • 1. [Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus. The GECMEI Group].
    Martínez Alfaro EM, Cuadra F, Solera J, Maciá MA, Geijo P, Sánchez Martínez PA, Rodríguez Zapata M, Largo J, Sepúlveda MA, Rosa C, Sánchez L, Espinosa A, Mateos F, Blanch JJ.
    Med Clin (Barc); 2000 Jul 01; 115(5):161-5. PubMed ID: 10996870
    [Abstract] [Full Text] [Related]

  • 2. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, Barry MA, O'Brien RJ.
    JAMA; 2000 Mar 15; 283(11):1445-50. PubMed ID: 10732934
    [Abstract] [Full Text] [Related]

  • 3. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.
    Rose DN.
    Ann Intern Med; 1998 Nov 15; 129(10):779-86. PubMed ID: 9841583
    [Abstract] [Full Text] [Related]

  • 4. [Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis].
    Martínez Alfaro E, Solera J, Serna E, Cuenca D, Castillejos ML, Espinosa A, Sáez L.
    Med Clin (Barc); 1998 Oct 10; 111(11):401-4. PubMed ID: 9834911
    [Abstract] [Full Text] [Related]

  • 5. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
    Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC, Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators.
    Ann Intern Med; 2002 Oct 15; 137(8):640-7. PubMed ID: 12379063
    [Abstract] [Full Text] [Related]

  • 6. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
    Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE, BRIEF TB/A5279 Study Team.
    N Engl J Med; 2019 Mar 14; 380(11):1001-1011. PubMed ID: 30865794
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis.
    Alaei K, Alaei A, Mansouri D.
    East Mediterr Health J; 2002 Nov 14; 8(6):754-7. PubMed ID: 15568452
    [Abstract] [Full Text] [Related]

  • 13. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.
    Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluuza Kityo C, Nsubuga P, Nakibali JG, Loughlin AM, Yun H, Mugyenyi PN, Vernon A, Mugerwa RD, Ellner JJ, Whalen CC, Uganda-Case Western Reserve University Research Collaboration.
    AIDS; 2001 Nov 09; 15(16):2137-47. PubMed ID: 11684933
    [Abstract] [Full Text] [Related]

  • 14. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK, Sharma A, Kadhiravan T, Tharyan P.
    Evid Based Child Health; 2014 Mar 09; 9(1):169-294. PubMed ID: 25404581
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
    Jansà JM, Serrano J, Caylà JA, Vidal R, Ocaña I, Español T.
    Int J Tuberc Lung Dis; 1998 Feb 09; 2(2):140-6. PubMed ID: 9580481
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis.
    Gourevitch MN, Hartel D, Selwyn PA, Schoenbaum EE, Klein RS.
    AIDS; 1999 Oct 22; 13(15):2069-74. PubMed ID: 10546859
    [Abstract] [Full Text] [Related]

  • 18. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials.
    Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M.
    AIDS; 1999 Mar 11; 13(4):501-7. PubMed ID: 10197379
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro.
    Souza CT, Hökerberg YH, Pacheco SJ, Rolla VC, Passos SR.
    Mem Inst Oswaldo Cruz; 2009 May 11; 104(3):462-7. PubMed ID: 19547873
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.